What MeiraGTx Holdings plc told the SEC could break it.

MeiraGTx has incurred significant recurring operating losses (net losses of $114.2 million in 2025 and $147.8 million in 2024) and had an accumulated deficit of $816.2 million at December 31, 2025, and it does not expect product-sales revenue until it completes clinical development and obtains regulatory approval; it therefore depends on collaboration upfronts/milestones (J&J, Lilly), at-the-market equity sales (~$76.5M available) and debt financing (e.g., Perceptive Notes with $135.0M due June 2026 and $50.0M due May 2027, plus warrants), so a funding shortfall or inability to hit milestones could force it to reduce or terminate operations.

“Our net losses for the years ended December 31, 2025 and 2024 were $114.2 million and $147.8 million, respectively. As of December 31, 2025, we had an accumulated deficit of $816.2 million.”

MeiraGTx's viral-vector and plasmid/DNA manufacturing is concentrated in its own facilities in London, United Kingdom and Shannon, Ireland, which it expects to supply its clinical, preclinical and third-party (e.g., J&J RPGR) obligations through approval and commercial production; if these facilities are damaged, suffer delays or regulatory challenges, or it cannot scale internal capacity to meet demand, it would need to contract with third-party manufacturers — a transition that could be slow, costly and disruptive to its programs and supply commitments.

“if our current facilities are damaged, suffer any form of delay or regulatory challenges, we experience slowdowns or problems with our facilities or we are unable to scale our internal manufacturing capabilities to meet demand for our product candidates, we will need to contract with third-party manufacturers to produce our product candidates.”

MeiraGTx depends on a limited number of suppliers for the manufacture of plasmid — a key component of its viral vectors and gene-therapy product candidates — and although it has built its own plasmid/DNA production capability in Shannon, Ireland, it still relies on third-party manufacturers for certain plasmid supply; it has no long-term supply agreements with these third-party manufacturers and purchases on a purchase-order basis, so a supplier disruption, capacity constraint or quality/regulatory failure could delay its programs and its third-party supply obligations.

“We currently have relationships with a limited number of suppliers for the manufacturing of plasmid, a component of our viral vectors and product candidates.”

MeiraGTx's value depends on obtaining regulatory approval for its AAV gene-therapy candidates (ophthalmology, salivary gland, neurodegenerative): it does not expect product revenue unless and until it successfully completes clinical development and obtains regulatory approval (or satisfies third-party supply obligations), key collaboration milestones are tied to regulatory approval of GMP manufacturing facilities in the U.S. and EU, and it is exposed to evolving U.S. drug-pricing regulation (Medicaid Drug Rebate Program changes and ACA); approval delays, denials or pricing pressure would materially impair its path to revenue.

“We do not expect to generate revenue from sales of products unless and until we successfully initiate and complete clinical development and obtain regulatory approval for any product candidates, or satisfy our third party obligations.”